Richter and Hetero collaborate on Ozempic generic
Hungary’s largest drugmaker Gedeon Richter (RICHT: HB) and Indian generics firm Hetero Labs have announced the signing of a global collaboration agreement to jointly develop, register and commercialize semaglutide injection (a generic version of Ozempic), further strengthening the parties' long-term partnership and expanding access to affordable treatments for patients worldwide.
Danish pharma major Novo Nordisk (NOV: N) developed and markets Ozempic for the treatment of diabetes. The drug generated sales of 127.09 billion Danish kroner ($18.5 billion) in 2025. It also markets semaglutide under the trade name Wegovy for obesity, which was the largest component of its weight loss revenues of 82,347 million kroner in 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze